| scholarly article | Q13442814 |
| P2093 | author name string | Paul Hyman | |
| Samuel Nurko | |||
| Miguel Saps | |||
| Carlo Di Lorenzo | |||
| Jose Cocjin | |||
| Adrian Miranda | |||
| Nader Youssef | |||
| P2860 | cites work | Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. | Q30350561 |
| Pharmacological interventions for recurrent abdominal pain (RAP) in childhood | Q31040374 | ||
| The Children's Depression, Inventory (CDI). | Q34201612 | ||
| Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders | Q34212933 | ||
| The placebo effect in irritable bowel syndrome trials: a meta-analysis | Q34421382 | ||
| New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline | Q34558362 | ||
| Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites | Q34706201 | ||
| Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints | Q36788794 | ||
| The placebo response in studies of acute migraine | Q37112070 | ||
| Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder | Q37338715 | ||
| Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial | Q39335444 | ||
| Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms | Q39366698 | ||
| Children's ibuprofen suspension for the acute treatment of pediatric migraine | Q39401917 | ||
| The word-graphic rating scale as a measure of children's and adolescents' pain intensity | Q42008983 | ||
| Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine | Q42111071 | ||
| Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment | Q43600172 | ||
| Evolution of visceral sensitivity in patients with irritable bowel syndrome | Q43980799 | ||
| Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation | Q46495622 | ||
| Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents | Q46645941 | ||
| Regional cerebral activity in normal and pathological perception of visceral pain | Q48824919 | ||
| A prospective school-based study of abdominal pain and other common somatic complaints in children. | Q50767265 | ||
| Quality of life for children with functional abdominal pain: a comparison study of patients' and parents' perceptions. | Q53263052 | ||
| Design of treatment trials for functional gastrointestinal disorders | Q60707889 | ||
| The Functional Disability Inventory: Measuring a Neglected Dimension of Child Health Status | Q67898407 | ||
| Morbidity in childhood--a longitudinal view | Q71280477 | ||
| Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children | Q73372196 | ||
| Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention | Q73719427 | ||
| Functional gastrointestinal disorders: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition | Q74644972 | ||
| Brief report: Assessment of children's gastrointestinal symptoms for clinical trials | Q77809463 | ||
| Recurrent abdominal pain: a five-year follow-up study | Q81894699 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amitriptyline | Q58397 |
| placebo | Q269829 | ||
| multicenter clinical trial | Q6934595 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 1261-1269 | |
| P577 | publication date | 2009-07-31 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders | |
| P478 | volume | 137 |
| Q33164288 | Adolescent fatigue, POTS, and recovery: a guide for clinicians |
| Q41186802 | Antidepressants for functional gastrointestinal disorders in children. |
| Q24235475 | Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents |
| Q38814244 | Approach to a Child with Functional Abdominal Pain |
| Q34175590 | Approaching patients with irritable bowel syndrome |
| Q36270698 | Assessment of abdominal pain through global outcomes and recent FDA recommendations in children: are we ready for change? |
| Q58548909 | Brain-Gut Axis: Clinical Implications |
| Q27024801 | Brain-gut axis: from basic understanding to treatment of IBS and related disorders |
| Q24234934 | Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome |
| Q38349884 | Childhood functional abdominal pain: mechanisms and management |
| Q35097188 | Childhood nonspecific abdominal pain in family practice: incidence, associated factors, and management |
| Q47811253 | Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial |
| Q59794335 | Cow's Milk Protein Allergy in Infancy: A Risk Factor for Functional Gastrointestinal Disorders in Children? |
| Q37800671 | Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome |
| Q57157613 | Design and reporting characteristics of clinical trials of select chronic and recurrent pediatric pain conditions: An ACTTION systematic review |
| Q38086233 | Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence |
| Q42698067 | Editorial: venlafaxine for functional chest pain: hope or hype? |
| Q34318616 | Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases |
| Q33459323 | Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. |
| Q44470627 | Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome |
| Q34093866 | Electrocardiograms changes in children with functional gastrointestinal disorders on low dose amitriptyline |
| Q38831882 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. |
| Q57489996 | Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives |
| Q35079445 | Functional abdominal pain and irritable bowel syndrome in children and adolescents |
| Q36859038 | Functional abdominal pain in childhood: background studies and recent research trends |
| Q44171259 | Functional gastrointestinal diseases in children: facing the rising tide |
| Q55339881 | Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. |
| Q39152817 | Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. |
| Q33625245 | Long-Term Study of Children With ROME III Functional Gastrointestinal Disorders Managed Symptomatically in a Biopsychosocial Model |
| Q33995802 | Management of functional abdominal pain and irritable bowel syndrome in children and adolescents |
| Q90483466 | Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome |
| Q38615854 | Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial |
| Q92142433 | New advances in the treatment of paediatric functional abdominal pain disorders |
| Q101403019 | Paediatric functional abdominal pain disorders |
| Q44737388 | Paediatric gastroenterology: EGD for children with abdominal pain: the jury is still out. |
| Q38808502 | Pain Measurement in Children with Functional Abdominal Pain. |
| Q34616113 | Pain and placebo in pediatrics: a comprehensive review of laboratory and clinical findings |
| Q36220453 | Pain management in patients with inflammatory bowel disease: insights for the clinician |
| Q41301800 | Pain reporting and analgesia management in 270 children with a progressive neurologic, metabolic or chromosomally based condition with impairment of the central nervous system: cross-sectional, baseline results from an observational, longitudinal st |
| Q38927580 | Pharmacological interventions for recurrent abdominal pain in childhood. |
| Q38258949 | Pharmacological treatment of chronic non-cancer pain in pediatric patients |
| Q38100087 | Placebo effects in children: a review |
| Q35204510 | Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients |
| Q38630447 | Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest |
| Q38189695 | Presentation and management of chronic pain |
| Q36203967 | Psychopharmacological treatment and psychological interventions in irritable bowel syndrome |
| Q38914226 | Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. |
| Q90472068 | Special considerations in conducting clinical trials of chronic pain management interventions in children and adolescents and their families |
| Q52677763 | The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence. |
| Q35088492 | The placebo effect and the autonomic nervous system: evidence for an intimate relationship |
| Q38221358 | The use of non-narcotic pain medication in pediatric gastroenterology |
| Q34770703 | Use of auricular acupressure to improve the quality of life in diabetic patients with chronic kidney diseases: a prospective randomized controlled trial |
| Q38240885 | Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia. |
| Q84806529 | [Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes] |
Search more.